These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11019427)

  • 21. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
    Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
    Mauro FR; Foa R; Meloni G; Gentile M; Giammartini E; Giannarelli D; De Propris MS; Rapanotti MC; de Fabritiis P; Mandelli F
    Haematologica; 2002 Sep; 87(9):926-33. PubMed ID: 12217804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
    Perkins JG; Flynn JM; Howard RS; Byrd JC
    Cancer; 2002 Apr; 94(7):2033-9. PubMed ID: 11932906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
    J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
    Liso V; Molica S; Capalbo S; Pogliani E; Battista C; Broccia G; Montillo M; Cuneo A; Leoni P; Specchia G; Castoldi G
    Haematologica; 2001 Nov; 86(11):1165-71. PubMed ID: 11694402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia.
    Giannopoulos K; Dmoszyńska A; Roliński J
    Leuk Res; 2007 Mar; 31(3):411-2. PubMed ID: 16978694
    [No Abstract]   [Full Text] [Related]  

  • 28. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
    Eichhorst BF; Busch R; Obwandner T; Kuhn-Hallek I; Herschbach P; Hallek M;
    J Clin Oncol; 2007 May; 25(13):1722-31. PubMed ID: 17389338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fludarabine for chronic lymphocytic leukemia.
    Copur MS; Ledakis P; Muhvic J
    N Engl J Med; 2001 Apr; 344(15):1166; author reply 1167-8. PubMed ID: 11302141
    [No Abstract]   [Full Text] [Related]  

  • 30. Oral fludarabine treatment of cutaneous infiltration in a patient with B-cell chronic lymphocytic leukaemia.
    Ural AU; Kubar A; Avcu F; Tastan HB; Safali M; Nevruz O; Cetin T
    Clin Exp Dermatol; 2007 Mar; 32(2):151-4. PubMed ID: 17244344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fludarabine in lymphoproliferative malignancies: a single-centre experience.
    Prabhash K; Vikram GS; Nair R; Sengar M; Gujral S; Bakshi A; Gupta S; Parikh PM
    Natl Med J India; 2008; 21(4):171-4. PubMed ID: 19267037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
    J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
    Robertson LE; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Plunkett W; Keating MJ
    Leukemia; 1995 Sep; 9(9):1444-9. PubMed ID: 7658710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine.
    Gonzalez H; Leblond V; Azar N; Sutton L; Gabarre J; Binet JL; Vernant JP; Dighiero G
    Hematol Cell Ther; 1998 Jun; 40(3):113-8. PubMed ID: 9698219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
    Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF
    Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission.
    Oudat R; Keating MJ; Lerner S; O'Brien S; Albitar M
    Leukemia; 2002 Apr; 16(4):632-5. PubMed ID: 11960343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab.
    Swords R; Nolan A; Fay M; Quinn J; O'Donnell R; Murphy PT
    Clin Lab Haematol; 2006 Feb; 28(1):57-9. PubMed ID: 16430461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
    Eichhorst BF; Busch R; Schweighofer C; Wendtner CM; Emmerich B; Hallek M;
    Br J Haematol; 2007 Jan; 136(1):63-72. PubMed ID: 17083342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fludarabine: new indication. First-line treatment of CLL: unconvincing evidence.
    Prescrire Int; 2005 Feb; 14(75):3-5. PubMed ID: 15747447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
    J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.